看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。1 X4 ]. @0 o" r! ?' }" p
% W* Z0 j# n( w7 ~5 ^; y
0 m! e# X& @6 x0 t1 CCurrently available feasibility data for possible combination strategies. + x- `5 Y( ~9 n* V; m/ w, m
————————————————————————————————- d- `" l7 Q3 p0 J
Combination Feasibility according to preliminary data 5 m9 @/ z- I" ?" I! c" J* ?7 w D0 m9 T
——————————————————————————————————, h0 P1 d1 F* Y# l( U- r
Bevacizumab + sorafenib Yes, reduced dose
% X& i/ C# |- b3 r8 y. ]. a( f4 hBevacizumab + sunitinib† No ! y, y% d1 R/ Q+ _
Bevacizumab + temsirolimus Yes
8 J3 |& f! O8 ]& B+ T* @4 ZBevacizumab + everolimus Yes
" x. G" M5 w/ A+ A2 y( ?Sorafenib + sunitinib ? . D7 i8 s9 m- Q+ u' K0 J
Sorafenib + temsirolimus Yes, reduced dose
! M% e! W: U# h+ W6 {5 i1 QSorafenib + everolimus Yes, reduced dose 4 ^$ ]9 e& i2 l3 y" n+ S
Sunitinib + temsirolimus† No
# V0 w# l# c1 _0 K" N) P; vSunitinib + everolimus ? ; t C& B& Z2 K. k, b
Temsirolimus + everolimus ?
: C8 C0 \' g+ y/ J1 a$ k————————————————————8 ^' a4 b& X5 F- {2 y: Q( f- \+ Q
†Led to US FDA warning.
. S4 N( M6 {4 h0 k) c?: As yet unattempted combination.& I% l) {* L& H D) ]( w& Q
|